drugset / Trial / NCT03823781
Prophylactic Use of Milrinone After Congenital Heart Surgery in Infants
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This randomized, multi-center, double-blinded, placebo-controlled study is designed to evaluate the efficacy and safety of milrinone compared with placebo in participants after corrective surgery for congenital heart disease. Participants will be randomized in a 1:1 ratio within 90 minutes after arriving in the intensive care unit (ICU), to receive either intravenous milrinone or placebo for 36 hours. Participants will be stratified according Vasoactive Inotrope Score after arriving in the ICU.
Timeline
- Start
- 2019-02
- Primary completion
- 2021-01
- Completion
- 2021-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Milrinone | Small molecule | 0.75 ug/kg | Intravenous |
Indications
No indication recorded.